"The U.S. Food and Drug Administration is alerting hospitals, health care professionals, and patients of a voluntary recall of all non-expired drug products produced and distributed for sterile use by Abrams Royal Compounding Pharmacy in Dallas, T"...
Neostigmine inhibits the hydrolysis of acetylcholine by competing with acetylcholine for attachment to acetylcholinesterase at sites of cholinergic transmission.It enhances cholinergic action by facilitating the transmission of impulses across neuromuscular junctions. It also has a direct cholinomimetic effect on skeletal muscle and possibly on autonomic ganglion cells and neurons of the central nervous system. Neostigmine undergoes hydrolysis by cholinesterase and is also metabolized by microsomal enzymes in the liver.Protein binding to human serum albumin ranges from 15 to 25 percent.
Following intramuscular administration, Neostigmine is rapidly absorbed and eliminated.In a study of five patients with myasthenia gravis, peak plasma levels were observed at 30 minutes, and the half-life ranged from 51 to 90 minutes. Approximately 80 percent of the drug was eliminated in urine within 24 hours; approximately 50% as the unchanged drug and 30 percent as metabolites. Following intravenous administration, plasma half-life ranges from 47 to 60 minutes have been reported with a mean half-life of 53 minutes.
The clinical effects of Neostigmine usually begin within 20 to 30 minutes after intramuscular injection and last from 2.5 to 4 hours.
Last reviewed on RxList: 6/26/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Neostigmine Methylsulfate Information
- Neostigmine Methylsulfate Drug Interactions Center: neostigmine methylsulfate inj
- Neostigmine Methylsulfate Side Effects Center
- Neostigmine Methylsulfate FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
Find out what women really need.